IQVIA Holdings/$IQV
1D1W1MYTD1Y5YMAX
Capital at risk
About IQVIA Holdings
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
- Ticker
- $IQV
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 94,000
- Headquarters
- Durham, United States
- Website
- www.iqvia.com
IQVIA Holdings Metrics
BasicAdvanced
$44B
32.99
$8.08
1.19
-
Price and volume
Market cap
$44B
Beta
1.19
52-week high
$273.88
52-week low
$154.50
Average daily volume
1.4M
Financial strength
Current ratio
0.706
Quick ratio
0.62
Long term debt to equity
2.213
Total debt to equity
2.578
Interest coverage (TTM)
3.07%
Profitability
EBITDA (TTM)
3,048
Gross margin (TTM)
32.97%
Net profit margin (TTM)
8.10%
Operating margin (TTM)
13.95%
Effective tax rate (TTM)
15.55%
Revenue per employee (TTM)
$180,000
Management effectiveness
Return on assets (TTM)
5.06%
Return on equity (TTM)
22.82%
Valuation
Price to earnings (TTM)
32.986
Price to revenue (TTM)
2.646
Price to book
7.11
Price to tangible book (TTM)
-2.89
Price to free cash flow (TTM)
20.573
Free cash flow yield (TTM)
4.86%
Free cash flow per share (TTM)
12.95
Growth
Revenue change (TTM)
8.17%
Earnings per share change (TTM)
16.67%
3-year revenue growth (CAGR)
4.98%
10-year revenue growth (CAGR)
14.21%
3-year earnings per share growth (CAGR)
11.57%
10-year earnings per share growth (CAGR)
9.28%
What the Analysts think about IQVIA Holdings
Analyst ratings (Buy, Hold, Sell) for IQVIA Holdings stock.
Analyst projections of the future price of IQVIA Holdings stock.
Bulls say / Bears say
Clinical demand is showing better forward visibility: second-quarter R&D net new bookings rose 19% to $3.15 billion, producing a 1.22 book-to-bill ratio. The $34.2 billion R&D backlog and expected 7.5% growth in next-twelve-month backlog revenue support the case for continued growth into 2027. (IQVIA, IQVIA)
IQVIA is embedding AI into both clinical and commercial services rather than treating it as a standalone product. Management said 294 AI agents were deployed across 90 use cases, with 19 of the top 20 pharmaceutical companies using its AI solutions and four of the top ten co-developing them. (Equibles, IQVIA)
The balance sheet remains heavily geared: net debt was about $14.1 billion and net leverage was 3.59 times adjusted EBITDA at the end of June. That leaves less financial flexibility if clinical-research demand or cash generation weakens. (Equibles, Simply Wall St)
The latest beat did not fully resolve profitability concerns: reported operating margin fell to 11.6% from 12.6% a year earlier, while quarterly free cash flow missed analysts’ estimates. Pass-through costs and lower-margin acquisitions could continue to limit margin expansion. (Yahoo Finance, StockStory)
The $34.2 billion backlog is not entirely risk-free: management is reviewing inactive trials and said a potential adjustment could be around 5%. Although it said this would not affect current guidance, it raises a question over how much of the headline backlog represents economically active work. (Equibles, StockStory)
Data summarised monthly by Lightyear AI. Last updated on 21 Sept 2026.
IQVIA Holdings Financial Performance
Revenues and expenses
IQVIA Holdings Earnings Performance
Company profitability
Upcoming events
No upcoming events
IQVIA Holdings News
AllArticlesVideos
IQVIA Announces Pricing of Senior Notes
Business Wire2 weeks ago
IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster
Business Wire3 weeks ago
IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare
Business Wire4 weeks ago
Funds containing IQVIA Holdings
AllUSDEURGBP
Fund name | Fund size | $IQV weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 1.78% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.78% |
iShares Healthcare Innovation£DRDR | £1B | 1.78% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 1.07% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.74% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.